Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting
The five platinum anticancer compounds currently in clinical use conform to structure–activity relationships formulated (M. J. Cleare and J. D. Hoeschele, Bioinorg. Chem., 1973, 2, 187–210) shortly after the discovery that cis-diamminedichloroplatinum(II), cisplatin, has antitumor activity in mice....
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Royal Society of Chemistry, The
2013
|
| Online Access: | http://hdl.handle.net/1721.1/82144 https://orcid.org/0000-0002-2693-4982 |
| _version_ | 1826206740125843456 |
|---|---|
| author | Lovejoy, Katherine S. Lippard, Stephen J. |
| author2 | Massachusetts Institute of Technology. Department of Chemistry |
| author_facet | Massachusetts Institute of Technology. Department of Chemistry Lovejoy, Katherine S. Lippard, Stephen J. |
| author_sort | Lovejoy, Katherine S. |
| collection | MIT |
| description | The five platinum anticancer compounds currently in clinical use conform to structure–activity relationships formulated (M. J. Cleare and J. D. Hoeschele, Bioinorg. Chem., 1973, 2, 187–210) shortly after the discovery that cis-diamminedichloroplatinum(II), cisplatin, has antitumor activity in mice. These compounds are neutral platinum(II) species with two am(m)ine ligands or one bidentate chelating diamine and two additional ligands that can be replaced by water through aquation reactions. The resulting cations ultimately form bifunctional adducts on DNA. Information about the chemistry of these platinum compounds and correlations of their structures with anticancer activity have provided guidance for the design of novel anticancer drug candidates based on the proposed mechanisms of action. This article discusses advances in the synthesis and evaluation of such non-traditional platinum compounds, including cationic and tumor-targeting constructs. |
| first_indexed | 2024-09-23T13:37:30Z |
| format | Article |
| id | mit-1721.1/82144 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T13:37:30Z |
| publishDate | 2013 |
| publisher | Royal Society of Chemistry, The |
| record_format | dspace |
| spelling | mit-1721.1/821442022-10-01T16:07:33Z Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting Lovejoy, Katherine S. Lippard, Stephen J. Massachusetts Institute of Technology. Department of Chemistry Lovejoy, Katherine S. Lippard, Stephen J. The five platinum anticancer compounds currently in clinical use conform to structure–activity relationships formulated (M. J. Cleare and J. D. Hoeschele, Bioinorg. Chem., 1973, 2, 187–210) shortly after the discovery that cis-diamminedichloroplatinum(II), cisplatin, has antitumor activity in mice. These compounds are neutral platinum(II) species with two am(m)ine ligands or one bidentate chelating diamine and two additional ligands that can be replaced by water through aquation reactions. The resulting cations ultimately form bifunctional adducts on DNA. Information about the chemistry of these platinum compounds and correlations of their structures with anticancer activity have provided guidance for the design of novel anticancer drug candidates based on the proposed mechanisms of action. This article discusses advances in the synthesis and evaluation of such non-traditional platinum compounds, including cationic and tumor-targeting constructs. National Cancer Institute (U.S.) (Grant CA34992) 2013-11-15T19:58:47Z 2013-11-15T19:58:47Z 2009-10 2009-07 Article http://purl.org/eprint/type/JournalArticle 1477-9226 1477-9234 http://hdl.handle.net/1721.1/82144 Lovejoy, Katherine S., and Stephen J. Lippard. “Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.” Dalton Transactions, no. 48 (2009): 10651. https://orcid.org/0000-0002-2693-4982 en_US http://dx.doi.org/10.1039/b913896j Dalton Transactions Creative Commons Attribution-Noncommercial-Share Alike 3.0 http://creativecommons.org/licenses/by-nc-sa/3.0/ application/pdf Royal Society of Chemistry, The PMC |
| spellingShingle | Lovejoy, Katherine S. Lippard, Stephen J. Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting |
| title | Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting |
| title_full | Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting |
| title_fullStr | Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting |
| title_full_unstemmed | Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting |
| title_short | Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting |
| title_sort | non traditional platinum compounds for improved accumulation oral bioavailability and tumor targeting |
| url | http://hdl.handle.net/1721.1/82144 https://orcid.org/0000-0002-2693-4982 |
| work_keys_str_mv | AT lovejoykatherines nontraditionalplatinumcompoundsforimprovedaccumulationoralbioavailabilityandtumortargeting AT lippardstephenj nontraditionalplatinumcompoundsforimprovedaccumulationoralbioavailabilityandtumortargeting |